A Phase 1 interventional study of warfarin and fostamatinib in Rheumatoid Arthritis and Healthy Subjects, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-31.
Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Arthritis, Rheumatoid by AstraZeneca — 4 open to participants now, 4 under way, none of them phase 3. Arthritis, Rheumatoid · AstraZeneca.
Among the 49 studies in Arthritis, Rheumatoid by AstraZeneca, this one is the 40th largest by enrollment of the 45 interventional ones that give a count, is one of 8 that started in 2011, is one of 22 in phase 1, and was the 22nd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 49 studies in Arthritis, Rheumatoid by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Australia, Germany and 3 more countries
Ages 18–75
AstraZeneca · Sites in United States, Argentina, Brazil and 14 more countries
Ages 18+
AstraZeneca · Sites in United States, Australia, Belgium and 7 more countries
Ages 18–65
AstraZeneca · Sites in United States, Canada, China and 7 more countries
Ages 18–70
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 17 · Phase 3 6
First in 2003; this study’s year is marked. 8 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 72 across the 45 interventional studies, 1,575 across the 4 observational. Of the 44 that completed or were terminated, 21 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
2 of the studies in Arthritis, Rheumatoid by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
| NCT07276581AstraZenecaA Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis | 2027-11-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 49 studies in Arthritis, Rheumatoid by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether fostamatinib influences the plasma concentration of warfarin and changes its blood thinning effect, and to investigate how safe and tolerable it is when administered with warfarin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: warfarin
Drug: warfarin · Drug: fostamatinib
2 single 25 mg doses of Warfarin (5 x 5 mg tablets) administered 14 days apart
Also known as: Marevan
2 x 50 mg Fostamatinib tablets (100 mg) twice daily for 13 days
To determine PK parameters of R- and S-warfarin including but not limited to AUC and Cmax
* Pharmacokinetics of warfarin measured by AUC * Pharmacokinetics of warfarin measured Cmax
Time frame: From pre-dose to 168 h post dose relative to each single warfarin dose
To measure International Normalised Ratio (INR) following administration of warfarin
Time frame: From pre-dose to 168 h post dose relative to each single warfarin dose
To assess the steady-state pharmacokinetics of R406 (active metabolite of fostamatinib) by measuring AUCss, Cmax,ss, tmax,ss and CL/F
* Steady state Pharmacokinetics of R406 measured by AUCss * Steady state Pharmacokinetics of R406 measured by Cmax * Steady state Pharmacokinetics of R406 measured by ss * Steady state Pharmacokinetics of R406 measured by tmax * Steady state Pharmacokinetics of R406 measured by CL/F
Time frame: From predose on Day 11 until 12 h post dose on Day 14 relative to fostamatinib dosing
Safety and tolerability will be measured with regard to adverse events, laboratory assessments, vital signs, physical examination, and 12-lead ECG will be recorded.
To examine the safety and tolerability of fostamatinib in combination with Warfarin: Adverse events, laboratory assessments, vital signs, physical examination, and 12-lead ECG
Time frame: From screening, Day -1 to Day 21 and follow up visit (Day 28)
The record gives a start of Mar 2011, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Warfarin